Thanks, everyone. This is day two of the Stephens Conference. I'm Mason Carrico. I'm the diagnostics and medtech analyst here. Happy to have Myriad joining us. We've got Ben Wheeler, CFO, and Matt Scalo, SVP of Investor Relations. First off, I guess, appreciate you guys being here. I want to say that.
Thanks for having us.
Happy to be here.
You guys just reported Q3. Maybe just the easiest place to start here is give us a quick overview of the quarter. What are your key takeaways? What do you want investors to focus on coming out of the print?
Yeah, absolutely. Coming out of Q2, we were keenly focused, coming into Q3, on our prenatal results. We were keenly focused on average revenue per test across the hereditary cancer tests, and also really focused on improving profitability or financial results. Q3 was a really important quarter for us. We were pleased to announce the prenatal sale, a $210 million cash deal. LabCorp is the buyer there, and pleased with the process we went through as it relates to the prenatal sale. I think we'll talk a little bit more about that in a few minutes. But important to find a home for that business that would enable continuity of care for patients and physicians. As we entered Q3, as I said, we were really focused on driving improvement in our average revenue per test for our hereditary cancer testing.
We implemented several efforts across the organization in order to buoy up the average revenue per test, and we saw some progress in Q3. We've got more work to do, but really pleased with the progress that we saw there. Again, as I said, strengthening the financial profile of the organization. We saw improvement in revenue of $10 million-$12 million in Q3, and ultimately all of that dropped through to the improvement in adjusted EBITDA. Maybe the last thing that I'll share is, as we think about driving growth for the organization, our MRD franchise is really important to us. During Q2, we were pleased to submit to MolDX for breast.
Also, coming out of Q3 at ESMO in October, we were really happy with the CRC data that we shared supporting the ultra-sensitivity of our test and the value that it brings in the CRC space.
Mm-hmm. Maybe on the prenatals sale, just walk us through, I guess, the timeline and process that ultimately led to the decision to sell that business. When, I guess, did thinking shift from fixing it to selling it?
Sure. I would start with when Sam transitioned into the seat as CEO and President of Myriad. One of his very first acts essentially was to evaluate and then define our growth strategy as an organization. In connection with that, he called out focus on the cancer care continuum as our primary area of focus. Secondarily, we would grow at or above market for mental health and prenatal health. Third, we would focus on improving profitability as we focus on growth. In connection with that, just an ongoing process of evaluating the performance of the portfolio of the various assets is something that Sam implemented. As we think about our prenatal asset group over the last six quarters, we were not growing at or above market.
We felt like it was important for us to be able to execute on that first strategic pillar to grow in the cancer care continuum and execute more effectively there. It was important to find a better home for the prenatal business. It was a robust process. We had a lot of interest in the assets, and ultimately, as I said a moment ago, felt like LabCorp was the best home for the assets and the employees. In connection with that transaction, and we shared on our Q3 results call, we expect our revenue growth rate to increase in excess of 100 basis points. We expect gross margins to increase in excess of 500 basis points. Then we also made reference to the fact that we've got 500 employees that are going to transition to the LabCorp business.
Mm-hmm. On those 500 employees that are transferring over, and I assume we'll probably get more of this as the sale closes and we look into 2027, but what does that cost base look like in terms of how much flows through COGS, how much through OpEx? How quickly can Ascend take out whatever stranded costs exist post-divestiture?
Yeah. The way that we framed it is of those 500 employees, about a third are directly associated with lab operations. So a third of them I would attribute to COGS, and that is considered when we talk about the 500 plus basis point improvement in our gross margins. The remaining employees would be part of the OpEx space. The way that I would think about that, particularly as it rolls through 2027 in connection with the Ascend initiative, is we expect the transaction to close in the first half of 2027, probably earlier than later, when we're thinking about the first half of 2027. It also will require some work to transition that business, and so there's costs in connection with that. So we would expect throughout the course of 2027 to see efficiencies on the OpEx side kind of phase in.
As you mentioned, we absolutely will give some more insight into the way that we're thinking about OpEx as a RemainCo in 2027 as we get a little bit closer.
Okay. On hereditary, ASP increased 9% sequentially, or at least close to that. I guess, how do you split that improvement between lapping some of the Q2 headwinds, improvements, or benefits that have been realized from revenue cycle management, MyRisk reimbursement initiatives? Maybe just walk us through kind of the improvement that you saw from Q2 to Q3.
Sure. I think about it this way. So in Q2, we called out $11 million in change in estimate or out-of-period revenue impact. In Q3, it was inconsequential impact. It was immaterial. A primary driver of the change in the impact is because of that work that was focused on revenue cycle management optimization. Mason, you called out the two initiatives that we have really focused on revenue cycle. One is the MyRisk ASP initiative, and the other one is a revenue cycle management optimization. I do not want to get lost in the details of what belongs where, but I think what is important to understand is, as we focus on improving execution, the tactical execution in RCM, to eliminate or alleviate some of that friction that we encountered in Q2, we saw improvement.
I would tie that to the side of revenue cycle management that, like I said, is tactical execution. It is prior authorization requirements, it is medical record retrieval, it is obtaining physician signatures in the right place for a payer's requirement.
Mm-hmm. Okay. Then on maybe just a little bit deeper there, the front-end prior auth verification, medical records integration. You have talked about AI-assisted appeals, things like that, payer-by-payer MyRisk efforts. Which do you see as the most critical or maybe the most important in terms of what it can provide over, let us just say, the next 12 months versus those that you obviously are going to continue to work on moving forward?
Yeah. I think when you follow a claim through the process from submission to payment, each of the tactical elements are, I would say, equally important. You can get a denial for all kinds of reasons. Maybe I'd frame it this way. As we focus on understanding and pivoting to any changes in prior authorization requirements and being able to do that very dynamically, very important. The ability to automate medical record retrieval, equally important. You're not going to get an approved claim if you're missing either one of those things. The tactical execution work that we were focused on in Q3, important to drive improvement. It's important to us that we continue to see that improvement as we get into Q4 and into 2027.
The payer-by-payer analysis, it's important in understanding what they're doing, how their claims are being processed, but it's also important for us to think through what is our strategy in strengthening and maintaining relationships with those payers as we think about coverage and medical policy.
Mm-hmm. Then maybe moving to volumes. Comps have made the growth rate a little bit different on a quarterly basis, right, throughout this year. But maybe just walk us through the key drivers in hereditary, unaffected and then affected, throughout 2026, and what you view as maybe some of the more material catalysts or drivers to MyRisk adoption over the next year or so.
Yeah. We've generally been pleased with the volume growth that we've seen both on the unaffected and affected side of our businesses. They're great markets. On the affected side of the house, you're talking about a $2 billion market. On the unaffected side of the house, you're talking about a $5 billion market. And there's penetration opportunity, lots more penetration opportunity on the unaffected side, but there's still a fair amount of opportunity on the affected side. And it's also unfortunate, but important to recognize, that cancer incidents continue to rise, which essentially expands the market opportunity. Additionally, when you think about guidelines from NCCN or otherwise that help a physician determine how to provide care to their patient, guidelines continue to strengthen the use of hereditary cancer testing. We made reference to some guideline expansion earlier in the year.
As you think about continuing to drive growth from a volume standpoint, both for the affected or unaffected side, it's important that we understand how a patient is, or excuse me, a physician is thinking about making decisions to treat their patient. We also think that it's really important to make sure that we're easy to work with. That's a focal point as we transition into 2027, is how can we make sure that a physician's interactions with us make it easier for them to treat their patients and continue to make us a provider of choice for hereditary cancer testing?
Okay. At a recent conference, you may have mentioned the NCCN updates, colorectal, maybe some gastric cancers, endometrial. I think at that time, and I hope I'm not quoting you wrong here, you talked about the benefits of that still being ahead of you from a volume perspective. When do you expect the effect of those updates to start flowing through, I guess, order volumes?
Yeah. I think there are two implications when I think about volume, and one is probably a little easier to see the direct correlation with volume, and the other, there's an indirect correlation with volume. But guideline changes, as I mentioned, impact the way a physician thinks about what testing to use to administer care to a patient. In the U.S., a guideline change does not result in immediate change of physician behavior. It just kind of bleeds into their practice. That's why we said, it is ahead of us. I wouldn't point to a specific quarter that we expect a change. It essentially serves as a tailwind to continue to support market growth. The other aspect of this is on the medical policy standpoint for payers. Payers have very different approaches to how they evaluate or utilize guidelines.
There are some payers that are very interested in making sure their medical policies are aligned to guidelines, and there are other payers that are less interested in that. From a medical policy standpoint, anytime a guideline changes, we have an opportunity to engage with a payer and encourage them to look at what those guidelines are and to think about that from a policy standpoint. From a minimum perspective, though, if we submit a claim for a patient that meets a guideline and a payer has denied that claim, when we appeal that denial, we can point at a guideline which strengthens your position. The same concept holds, though. There's not going to be a quarter or a specific period that we're going to see a change across the payer landscape from a medical policy standpoint or viewpoint.
It's going to kind of be drips and drabs, but it gives you an opportunity to go out and engage with them. Again, supporting the tailwind perspective that there's growth in this market and there's opportunities to drive increased volume.
Yep, that makes sense. Maybe pivoting to Precise MRD. You said you submitted the breast indication. I think you guys are still expecting reimbursement in the first half of 2027. Once coverage is secured, how quickly do you pivot to driving volumes, or do you keep managing demand until you secure more indications?
Yeah, so we're very excited about our MRD franchise. As I mentioned a few minutes ago, we submitted our initial package to MolDX during Q2. It was in the middle of July that we submitted that for breast was the first indication. Our expectation is that, based on what we've observed in the market and our relationship with MolDX across coverage for other products historically in the portfolio, we expect nine to 12 months to transition from submission to approval. Our expectation is that we will have approval for that breast indication in the first half of next year, probably late in the first half of next year. We also shared on our Q3 earnings call that CRC and renal will be our next submissions to MolDX, and we expect that to take place over the course of the next several months.
We have our renal data, and that has been included in a publication. Our CRC data was presented at ESMO in October, and we are really pleased with the strength of that data. That is the data that will support that CRC application to MolDX. Tying that to the end of your question, the way that we are thinking about volume from MRD, in 2027, we are going to look to meter volume. I think we will approach ramping that volume more significantly as we see multiple approvals. As you think about the way that volume flows through a physician's practice, as we manage the implications to the financials, broader reimbursement strengthens the approach to amplifying volume or accelerating volume.
Yeah, that makes sense. What is it, ovarian and endometrial that are coming next? How are you thinking about the pacing of those submissions beyond renal and CRC?
Yeah, that is exactly right. Those are the next two indications on the product roadmap, and I think it was in January, Sam shared at a conference that our roadmap shows that we will submit endometrial and ovarian in 2027. Our expectation is that it would be late in 2027.
Okay.
We are still marching towards each of those timelines in connection with all five of those indications. Again, something that we are excited about as we advance the MRD franchise, recognizing the line of indications that we have coming.
Could you just remind us of the commercial team rep size strategy for Precise MRD, your thoughts around investments there over 2027 as these indications start to roll in?
Yeah, so when I think about investments for Precise MRD, I think about it in two ways. One is clinical spend, and then two is commercial investment. From a clinical standpoint, we have over a dozen trials in process right now. We will continue to invest in those trials and would expect that there will be some incremental cost for Precise MRD from a clinical standpoint in 2027 relative to 2026. From a commercial investment standpoint, we have talked throughout the year about adding about 100 sales folks to our commercial teams during 2026. We shared on our Q3 call that about 30% of those attributable to prenatal. The remaining 70 really focused on, we will say, unaffected or affected hereditary cancer. There is a small group that is a specialty group that we have hired focused on Precise MRD.
The way that we think about that is we have got the specialty Precise MRD sales force that is available to engage with customers directly, particularly the larger healthcare systems, but they also work as the central resource, the expertise for a broader oncology sales force, so that essentially, the Precise MRD sales force can amplify what they do through that oncology group as the oncology group engages with community doctors across the country.
Okay, that makes sense. Kind of an off-topic question to some degree. Can Precise Tumor and Precise MRD be run off of the same tissue? I guess, how do you think of the ability to offer both of those to a clinician in terms of, I guess, the value pitch to clinicians, as Precise MRD kind of comes to market and you start to push it commercially?
Yeah, I think it's a great question. We view bringing multiple offerings to the community oncologist as a key part to driving success. Tissue acquisition and then processing the sample using that tissue absolutely enables scale and, we'll just say, ease of use with the physician. It is a focal point of ours to make sure that that process is as easy as it can be.
Okay. Maybe pivoting to prostate. I think this year, Prolaris + AI returning to growth, volumes excelled. That was the initial thought process as you've kind of upgraded that test. I think there's been an NCCN guideline change. You guys called this out on the 3Q call that kind of weighed on volumes. I guess, how are you thinking about the outlook now for Prolaris, given this guideline change? Maybe beyond that, I think that with the preliminary clinical lab fee schedule, there were some potential ASP headwinds too. Just an overall view of kind of where Prolaris stands today and how you're thinking about it moving forward.
Yeah, so maybe I'll start with pricing, then I'll come back to the volume piece. We estimate the impact of PAMA across our portfolio to be about $8 million-$10 million. The lion's share of that is within CCC because of Prolaris.
Yep.
We do expect a headwind to ASP as we transition into 2027, specific to Prolaris. As it relates to volume, we don't expect the guideline change to alleviate. We think that there's going to be a modest headwind from a volume standpoint because of that guideline change. Having said that, we've been really pleased with the feedback that we've gotten on Prolaris + AI. It's enabled us to win back some customers. We've been happy to see some better depth in volume from prescribing physicians. We will continue to make sure that folks recognize what it is, what the value is, that we have combined a genomic result with an AI result that are tied together so that oftentimes the physician, they can use another provider and they can get an AI result, they can get a genomic result. Sometimes you got to figure out what that means together.
Right.
We have an integrated report that provides that insight, and I think that's impactful to folks. One of the things that we'll do to work in effort to overcome the modest headwind from the guideline change is to drive volume because of the AI component that we can offer. Then maybe the last thing I'll share relative to Prolaris is, again, as we think about guidelines, in recent years, hereditary cancer testing has become important when treating prostate cancer. Again, as a provider, to try and make things as simple as possible for a physician, if you're going to get a genomic test with an AI component and you need a germline test, we're the provider that can offer that. That's not something you can find somewhere else under one roof.
Okay. I think at a recent conference, you may have talked about other portfolio decisions being possible at Myriad. I guess, how should investors think about whether GeneSight is core to the new Myriad?
Yeah, so I would think about it this way. Cancer care is our primary focus. We believe that it is important to be able to grow at or above market and to do so profitably. That is the three pillars of the strategy, right? We have been pleased with the performance of GeneSight. In early 2025, we took a very hard look at the resources that we were using to drive that business, and we have been really pleased with the results of being able to grow in, we will say, mid-single digits with confined resources.
We have also talked a little bit about the profitability profile of that business. From a gross margin standpoint, it generates gross margins above the corporate average, the current corporate average. And then maybe the last thing from a profitability standpoint, as we have focused the resources to support that business, we approach profitability. So, when I think about, is it core to the cancer care continuum? It is not, but it also is a business that is growing with the resources that we have defined as appropriate, and we are satisfied with the growth that we are seeing. So, we are pleased with the GeneSight team, and I would just think about those two things, right? It is not core. We recognize that it is not core. It is also a business that is performing at our expectation.
Okay. Then maybe pivoting to Ascend. I think you guys recently talked about six value streams, with revenue cycle management and customer service being some of the large opportunities there. How much of the Ascend opportunity, I guess, is revenue yield, if that is the right way to call it, or describe it, and how much is cost?
Yeah.
Just, yeah, at a high level.
Absolutely. We see meaningful opportunity on both the revenue and the cost side. I want to make sure that folks understand, Ascend is enabled in an amplified way by divesting the prenatal assets, but Ascend is not simply to try and eliminate trapped overhead. Ascend is an initiative that we believe, as we advance, it will enable us to be more scalable, it will make us more efficient and more effective. As I said, I think it is enabled in a special way as you separate assets. To your point, we have identified six different value streams. Some of those are cost-focused, some of them are revenue-focused, and we think that there is meaningful opportunity in both of those areas. This is also going to be a multi-period initiative.
As you think about those different value streams, some of what will enable capability are related to new tools or changing processes or realigning the way that we do some of our work. Those things are not one-week or two-month things. Some of those things will take several quarters. We expect to see some benefit in 2027, both on the revenue and the cost side, and then naturally, as you get into 2028 and you have an annual impact, you also have had multiple quarters that you can deploy different capabilities and changes. We see it being a meaningful improvement to our financial profile.
Okay. Yeah, that makes sense. Another thing I wanted to hit on is, I think you guys recently called out a desire to bring a liquid-based therapy selection test to market over the next maybe 12-18 months. Could you just expand on that a bit? It's something that you guys haven't talked a lot on, at least relatively recently, just that opportunity in general.
Yeah, so that fits right in with my comment about our view that providing a broader range of solutions to a physician is important in driving growth and, frankly, winning in the market. When you think about the portfolio that we have today with industry-leading hereditary cancer testing, we have an HRD test that's used in treating ovarian cancer, and we have a tissue CGP. I think we have opportunities to strengthen that product offering, but we have that in the market today and see that there's tremendous value in providing a tissue CGP to a community oncologist. A product offering that we lack would be a liquid CGP offering. We've talked about it in the past, not a lot recently, but we view opportunities to bring that type of offering to market through partnership or through development, that we have a relationship with SOPHiA GENETICS.
We also look at broader partnership opportunities where we could bring a liquid offering. Again, I would think about it in the context of, as we evaluate how we can drive success with community oncologists, the broad offering is important. So what else is there? We continue to think about those things too. I think about it more as like a window into how we're seen competing and winning in the market, and maybe less so about a specific timeline that we should start communicating bringing that particular offering.
Okay. Then as we kind of move towards wrapping up here, on guidance for the year, I guess ignoring prenatal, when you look at, I guess, the full-year guide for the cancer care continuum plus mental health, that revenue number, it assumes a step-down in Q4. Your margin guidance assumes a step-down in Q4. I guess, what's driving that? Is this more of a product of ensuring that an appropriate amount of conservatism is kind of baked into the outlook? Any insight into how we should be thinking about the Q4 quarter from that sense?
Sure. I think there's two things to think about there. One is, as we came out of Q3, we'd established guidance, and ultimately, when we reframed the guidance, we took the Q3 beat. Baked it into a new annual number, and then we offset that with some softening of prenatal because of the deal announcement. Really, those were the mechanics of updating the guidance. Now, the reason that we didn't get more detailed about, in that recasting from a volume and ASP standpoint across the product portfolio, was because we really see it is important that we meet and exceed expectations. I feel like the answer to the conservatism question is, yeah, we think it's important to make sure that we're conservative in our assumptions.
We are focused on driving volume and ASP improvement across the portfolio, but really, the mechanics of the updated guide were you bank the Q3 beat and you offset it by some volume risk because you've just announced a deal.
Okay. To wrap up, looking into 2027, recognizing you are not going to give us guidance, and that is fine, but I guess just the building blocks of Myriad moving forward. Hereditary has been probably a high single-digit grower if you look at last year and then average out the volume growth throughout this year. You have given some commentary on the way to think about ASP there. Maybe at a high level, kind of running through how you are thinking about the RemainCo and what we should be focusing on in 2027 as we move into the new year.
Sure. Yeah. You hit the primary pieces or building blocks for hereditary cancer. When we think about 2027 growth profile from a volume versus average revenue per test, I think on the GeneSight front, we expect to maintain stable ASP and volumes to continue to grow at market, which we believe is mid-single digits. As we think about focus for 2027, I would really highlight three things. One is execution and close transition the prenatal business to LabCorp. So, great line of sight. We are marching towards that timeline. There is effort that goes into transitioning a business. So, we will execute on that and get it done, primary area of focus. Number two, making sure that we are driving growth in hereditary cancer.
Again, we want to make sure that the user experience with physicians is strong, and we want to make sure that we are doing our work from a revenue cycle management standpoint to minimize the natural headwind associated with that business and do all that we can to make sure that we have strong revenue for hereditary cancer testing. The third thing from an area of focus is to improve profitability as we make sure that we are more efficient, we are more effective as we run the organization, as we build the new Myriad. I alluded to this in a comment before. We view this combination of selling the prenatal assets and our Ascend initiative as a really unique opportunity in a sense, where we can streamline or simplify our business, and then we can also focus our business and our energy and efforts to execute.
That combination of simplification and focus, I think, can be a powerful thing. So, we have done a lot of work recently. We know that there is a lot of work ahead, and we are excited about what we are going to accomplish as we combine that simplification and focus.
That's perfect. We can stop there. Thank you, guys.
Thank you.
Thanks.